ArticleInternational journal of cancer2019
Combined genetic and epigenetic alterations of the TERT promoter affect clinical and biological behavior of bladder cancer.
Abstract read
In one paragraph
Article in International journal of cancer, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 55 papers, 2 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
55citing papers in PubMed, 2 pooled it
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
55 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- The role of telomerase reverse transcriptase (TERT) promoter mutations in prognosis in bladder cancer.Bioengineered · 2021Pooled it
- Telomerase activation in the treatment of aging or degenerative diseases: a systematic review.Molecular and cellular biochemistry · 2021Pooled it
- Telomerase Activity in Melanoma: Impact on Cancer Cell Proliferation Kinetics, Tumor Progression, and Clinical Therapeutic Strategies-A Scoping Review.Current oncology (Toronto, Ont.) · 2026Review
- Balancing Early Detection and Overtreatment in Prostate Cancer: The Emerging Role of EpihTERT.Cancers · 2025Article
- The SPINK Protein Family in Cancer: Emerging Roles in Tumor Progression, Therapeutic Resistance, and Precision Oncology.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Article
- Chromosomal instability by low-coverage whole-genome sequencing assay predicts prognosis in bladder cancer patients underwent radical cystectomy.BMC medical genomics · 2025Article
- Exploring The Prevalence of Telomerase Reverse Transcriptase Promoter Mutations in Bladder Cancer Patients and Their Correlation with Tumor Characteristics.Asian Pacific journal of cancer prevention : APJCP · 2025Article
- Spontaneous Necrosis of a High-Risk Bladder Tumor Under Immunotherapy for Concurrent Malignant Melanoma: Role of BRAF Mutations and PD-L1 Expression.Biomedicines · 2025Article
- Bispecific antibodies as powerful immunotherapeutic agents for urological cancers: Recent innovations based on preclinical and clinical evidence.International journal of biological sciences · 2025Review
- Biological functions of 5-methylcytosine RNA-binding proteins and their potential mechanisms in human cancers.Frontiers in oncology · 2025Review
- TERT upstream promoter methylation regulates TERT expression and acts as a therapeutic target in TERT promoter mutation-negative thyroid cancer.Cancer cell international · 2024Article
- Article
- Risk stratification by combining common genetic mutations and TERT promoter methylation in papillary thyroid cancer.Endocrine · 2024Article
- Review
- Telomerase Reverse Transcriptase-Promoter Mutation in Young Patients with Bladder Tumors.Current issues in molecular biology · 2024Article
- Long non-coding RNAs: regulators of autophagy and potential biomarkers in therapy resistance and urological cancers.Frontiers in pharmacology · 2024Review
- Article
- Review
- Tumor-Agnostic Circulating Tumor DNA Testing for Monitoring Muscle-Invasive Bladder Cancer.International journal of molecular sciences · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
31 authors.
Ricardo LeãoDivision of Urology, Department of Surgery, University of Toronto, Toronto, ON, Canada.
Donghyun LeeArthur and Sonia Labatt Brain Tumor Research Center, The Hospital for Sick Children, University of Toronto, Toronto, ON, Canada.
Arnaldo FigueiredoFaculty of Medicine, University of Coimbra, Coimbra, Portugal.
Thomas HermannsDepartment of Urology, University Hospital Zürich, University of Zürich, Zürich, Switzerland.
Peter WildInstitute of Pathology and Molecular Pathology, University Hospital Zürich, University of Zürich, Zürich, Switzerland.
Martin KomosaArthur and Sonia Labatt Brain Tumor Research Center, The Hospital for Sick Children, University of Toronto, Toronto, ON, Canada.
Irene LauArthur and Sonia Labatt Brain Tumor Research Center, The Hospital for Sick Children, University of Toronto, Toronto, ON, Canada.
Mathew MistryArthur and Sonia Labatt Brain Tumor Research Center, The Hospital for Sick Children, University of Toronto, Toronto, ON, Canada.
Nuno Miguel NunesArthur and Sonia Labatt Brain Tumor Research Center, The Hospital for Sick Children, University of Toronto, Toronto, ON, Canada.
Aryeh J PriceDivision of Biology and Biological Engineering, California Institute of Technology, Pasadena, CA.
Cindy ZhangArthur and Sonia Labatt Brain Tumor Research Center, The Hospital for Sick Children, University of Toronto, Toronto, ON, Canada.
Tatiana LipmanArthur and Sonia Labatt Brain Tumor Research Center, The Hospital for Sick Children, University of Toronto, Toronto, ON, Canada.
Cédric PoyetDepartment of Urology, University Hospital Zürich, University of Zürich, Zürich, Switzerland.
Nadejda ValtchevaInstitute of Pathology and Molecular Pathology, University Hospital Zürich, University of Zürich, Zürich, Switzerland.
Kathrin OehlInstitute of Pathology and Molecular Pathology, University Hospital Zürich, University of Zürich, Zürich, Switzerland.
Hugo CoelhoDepartment of Urology, Coimbra University Hospital, Coimbra, Portugal.
Rashid SayyidDivision of Urology, Department of Surgery, University of Toronto, Toronto, ON, Canada.
Ana Melo GomesDepartment of Pathology, Coimbra University Hospital, Coimbra, Portugal.
Ligia Prado E CastroDepartment of Pathology, Coimbra University Hospital, Coimbra, Portugal.
Joan SweetDepartment of Pathology, University Health Network, Toronto, ON, Canada.
João VinagreInstitute for Research and Innovation in Health, (I3S), Institute of Molecular Pathology and Immunology of the University of Porto (Ipatimup), Porto, Portugal.
Joana ApolónioDepartment of Biomedical Sciences and Medicine, University of Algarve, Faro, Portugal.
Derek StephensBiostatistics, Design and Analysis, The Hospital for Sick Children, Toronto, ON, Canada.
Inês FaleiroDepartment of Biomedical Sciences and Medicine, University of Algarve, Faro, Portugal.
Kamel FadaakDivision of Urology, Department of Surgery, University of Toronto, Toronto, ON, Canada.
Patrick O RichardDivision of Urology, Department of Surgery, University of Toronto, Toronto, ON, Canada.
Girish KulkarniDivision of Urology, Department of Surgery, University of Toronto, Toronto, ON, Canada.
Alexandre R ZlottaDivision of Urology, Department of Surgery, University of Toronto, Toronto, ON, Canada.
Robert J HamiltonDivision of Urology, Department of Surgery, University of Toronto, Toronto, ON, Canada.
Pedro Castelo-BrancoDepartment of Biomedical Sciences and Medicine, University of Algarve, Faro, Portugal.
Uri TaboriArthur and Sonia Labatt Brain Tumor Research Center, The Hospital for Sick Children, University of Toronto, Toronto, ON, Canada.ORCID 0000-0002-5019-2683
Funding
CIHR MOP 137899
Abstract
In urothelial bladder cancer (UBC), risk stratification remains an important unmet need. Limitless self-renewal, governed by TERT expression and telomerase activation, is crucial for cancer progression. Thus, telomerase activation through the interplay of mutations (TERTp
Indexed as
DNA MethylationMutationDisease ProgressionEpigenesis, GeneticFemaleGene Expression ProfilingGene Expression Regulation, NeoplasticHumansMalePrognosisPromoter Regions, GeneticSequence Analysis, RNATelomeraseUp-RegulationUrinary Bladder NeoplasmsTelomeraseTERT protein, humanprogressionrecurrencetelomeraseTERT promoter methylationTERT promoter mutationsurothelial bladder cancer
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.